



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Lawrence B. Bugaisky
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Albert L. Ferro
Donald R. Banowit
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn P. Guest

George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Jyoti C. Iyer
Laura A. Vogel

Michael J. Mancuso
Bryan S. Wade
Aaron L. Schwartz
Michael G. Penn
Shannon A. Carroll
Wesley W. Jones
Matthew E. Kelley
Nicole R. Kramer

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Michelle K. Holoubek
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey Mills

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie
*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

June 3, 2005

WRITER'S DIRECT NUMBER:
(202) 772-8637
INTERNET ADDRESS:
KAREN@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1642

Re: U.S. Utility Patent Application
Application No. 09/720,086; § 371 Date: July 23, 2001
For: **De Novo DNA Cytosine Methyltransferase
Genes, Polypeptides and Uses Thereof**
Inventors: Li *et al.*
Our Ref: 0609.4560002/KRM/DJN

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Statement of Substance of Examiner Interview; and
2. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

KRM/DJN:dbj
Enclosures

406036_1.DOC



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Li *et al.*

Confirmation No.: 6968

Appl. No. 09/720,086

Art Unit: 1642

§ 371 Date: July 23, 2001

Examiner: Harris, A.M.

For: ***De Novo* DNA Cytosine
Methyltransferase Genes,
Polypeptides and Uses Thereof**

Atty. Docket: 0609.4560002/KRM/DJN

Statement of Substance of Examiner Interview

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants wish to thank Examiner Harris for the telephonic interview conducted on May 3, 2005. The Examiner Interview Summary, mailed May 4, 2005, accurately reflects the substance of the interview, however, in accordance with 37 C.F.R. § 1.133(b) and MPEP § 713.04, the following statement of the substance of the interview is provided by Applicants.

Applicants discussed with the Examiner the recent sequencing results of ATCC Deposit Nos. 209933, 209934 and 98809, corresponding to SEQ ID NOS:1-3, respectively. As explained on page 14 of their Amendment and Reply Under 37 C.F.R. § 1.116, filed March 10, 2005, under the heading "*Priority*," the sequencing was done to confirm that the nucleotide sequence amendments made to SEQ ID NOS:1-3 on July 23, 2001 corresponded to the sequences contained within ATCC Deposit Nos. 209933, 209934 and 98809.

Applicants confirmed that the nucleotide amendments to SEQ ID NOS:1-2 corresponded with the sequences contained within ATCC Deposit Nos. 209933 and 209934. Applicants also noted that the nucleotide amendments to SEQ ID NO:3 corresponded with

the sequence contained within ATCC Deposit No. 98809, except that the deposited clone exhibited a deletion of about 50 nucleotides within the coding region of SEQ ID NO:3. Finally, Applicants noted SEQ ID NO:3 as originally filed in U.S. Appl. Nos. 60/090,906 and 60/093,993, to which priority is claimed, did not harbor the deletion, and that the deletion was likely the result of cloning error in constructing the clone for deposit at the ATCC.

Applicants discussed submitting a Declaration attesting that the amended SEQ ID NOS:1-2 are supported by ATCC Deposit Nos. 209933 and 209934. In addition, Applicants discussed submitting a second Declaration attesting that amended SEQ ID NO:3 is supported by the combination of ATCC Deposit No. 98809 *and* SEQ ID NO:3 as originally filed in prior Appl. Nos. 60/090,906 and 60/093,993. The Examiner encouraged the filing of these two Declarations in order to support Applicants' prior requests for priority benefit of these two applications.

Applicants respectfully request that the substance of the interview be recorded. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz

Agent for Applicants

Registration No. 36,351

Date: 6/3/05
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600